Harvard Bioscience, Inc.
HBIO
$6.04
$0.030.50%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 93.20% | -15,916.67% | 74.36% | 22.04% | -972.43% |
| Total Depreciation and Amortization | -18.43% | -23.30% | -27.05% | -10.27% | -7.07% |
| Total Amortization of Deferred Charges | 240.46% | 536.73% | 301.12% | 200.00% | 87.14% |
| Total Other Non-Cash Items | -99.64% | 283.48% | -77.49% | -76.40% | 1,792.36% |
| Change in Net Operating Assets | -77.39% | -54.81% | -45.08% | 276.74% | 105.62% |
| Cash from Operations | -122.17% | -105.57% | 228.74% | 425.65% | 112.83% |
| Capital Expenditure | 16.96% | -49.17% | 76.48% | 89.12% | 20.47% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -14.12% | 9.09% | 38.96% | -111.29% | -140.48% |
| Cash from Investing | 9.22% | -28.54% | 68.68% | -150.87% | -203.56% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -3,335.00% | 0.00% | 67.21% | 71.62% |
| Issuance of Common Stock | -- | -99.38% | -100.00% | -75.66% | -- |
| Repurchase of Common Stock | 60.00% | 89.00% | -- | 100.00% | -59.57% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 0.00% | -- | -57.76% | -- | -- |
| Cash from Financing | 99.25% | 280.47% | -160.74% | -810.73% | -14.12% |
| Foreign Exchange rate Adjustments | -166.37% | 111.85% | -122.43% | 15,700.00% | 324.50% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -205.42% | 489.80% | -219.96% | 1,015.94% | 5,235.71% |